Alliancebernstein L.P. Has $507.98 Million Holdings in Abbott Laboratories $ABT

Key Points

• Alliancebernstein L.P. has reduced its stake in Abbott Laboratories by 0.4% during the first quarter, now holding 3,829,459 shares worth approximately $508 million.
• Multiple institutional investors increased their positions in Abbott, with significant purchases including a new stake worth $1.66 billion by Nuveen LLC and an increase of over 15,000% by GAMMA Investing LLC.
• Abbott Laboratories reported earnings of $1.26 per share for the last quarter, matching consensus estimates, and its revenue grew by 7.4% year-over-year, amounting to $11.14 billion.

Alliancebernstein L.P. lowered its position in Abbott Laboratories (NYSE:ABT - Free Report) by 0.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,829,459 shares of the healthcare product maker's stock after selling 15,139 shares during the quarter. Alliancebernstein L.P. owned approximately 0.22% of Abbott Laboratories worth $507,978,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kelly Financial Services LLC purchased a new position in Abbott Laboratories in the first quarter valued at about $216,000. Bank Pictet & Cie Europe AG lifted its position in shares of Abbott Laboratories by 1.9% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after buying an additional 2,774 shares during the last quarter. Edge Financial Advisors LLC lifted its position in shares of Abbott Laboratories by 3.3% in the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after buying an additional 81 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth about $84,418,000. Finally, Cerity Partners LLC lifted its position in shares of Abbott Laboratories by 49.8% in the first quarter. Cerity Partners LLC now owns 1,507,268 shares of the healthcare product maker's stock worth $199,939,000 after buying an additional 501,200 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company's stock, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Performance

Shares of ABT stock traded up $0.11 during trading hours on Friday, reaching $132.92. 3,286,796 shares of the company's stock were exchanged, compared to its average volume of 5,085,004. The business has a fifty day moving average price of $130.68 and a 200-day moving average price of $131.39. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $231.33 billion, a P/E ratio of 16.66, a P/E/G ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were issued a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories's dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ABT shares. Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and boosted their price target for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Mizuho boosted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 16th. Wells Fargo & Company reduced their price target on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research report on Friday, July 18th. Raymond James Financial reduced their price target on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating for the company in a research report on Friday, July 18th. Finally, Leerink Partners assumed coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.